On Tuesday, the U.S. Supreme Court will be discussing the use of mifepristone, a medication that was involved in over half of the abortions performed in the United States last year.

After reversing the constitutional right to an abortion two years ago, this is the first case regarding abortion that the court has encountered. In the time following, multiple states governed by Republicans have imposed bans or limitations on abortion access.

By early summer, a decision will be made regarding restricting access to the drug. This could have significant implications for the FDA’s control over drug safety. Some potential restrictions being considered are stopping mail delivery of the medication, limiting telehealth prescriptions, and shortening the time frame in which it can be used for pregnancy from 10 weeks to seven.

The FDA-approved drug, mifepristone, is deemed one of the safest by the Biden administration and Danco Laboratories, based in New York.

Since the year 2000, more than 6 million individuals have utilized the drug known as mifepristone. Medical professionals are worried that if mifepristone is not accessible or difficult to obtain, there may be a tendency to solely rely on misoprostol, another medication used in a medicated abortion that may not be as successful in terminating pregnancies on its own.

On the other hand, critics of abortion in the medical field argue that the FDA’s previous decision to loosen restrictions on acquiring the medication was unjustified and may negatively impact women’s well-being.

The Biden administration and drug companies are warning that a decision restricting access to mifepristone could have negative effects on the FDA’s process for approving drugs, as it could lead to more questioning of the agency’s scientific evaluations in court.

The White House has openly supported access to abortion.

The administration and Danco also maintain that the plaintiffs do not have sufficient legal grounds to file a lawsuit; if the Supreme Court agrees, the case would essentially be thrown out, rendering the previous appellate decision meaningless.

The court has added another abortion case to the list of cases to be addressed. This particular case deals with whether hospitals, in accordance with a federal law, are required to provide emergency treatment that includes abortions, even in states where they are prohibited.

Information for this report was contributed by The Associated Press and Reuters.